Compare Pharmaron Beijing Co., Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- The company is Net-Debt Free
2
With ROE of 8.98%, it has a Very Expensive valuation with a 0.35 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
97.42%
0%
97.42%
6 Months
73.37%
0%
73.37%
1 Year
15.3%
0%
15.3%
2 Years
188.68%
0%
188.68%
3 Years
79.37%
0%
79.37%
4 Years
-16.05%
0%
-16.05%
5 Years
-83.47%
0%
-83.47%
Pharmaron Beijing Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.77%
EBIT Growth (5y)
11.79%
EBIT to Interest (avg)
9.48
Debt to EBITDA (avg)
0.84
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
0.59
Tax Ratio
19.59%
Dividend Payout Ratio
22.45%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.31%
ROE (avg)
12.92%
Valuation key factors
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
0.35
EV to EBIT
4.70
EV to EBITDA
3.23
EV to Capital Employed
0.47
EV to Sales
0.67
PEG Ratio
NA
Dividend Yield
1.00%
ROCE (Latest)
10.02%
ROE (Latest)
8.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
4,623.60
4,038.00
14.50%
Operating Profit (PBDIT) excl Other Income
1,027.70
936.10
9.79%
Interest
55.70
58.20
-4.30%
Exceptional Items
71.20
-9.20
873.91%
Consolidate Net Profit
461.90
350.30
31.86%
Operating Profit Margin (Excl OI)
132.30%
130.90%
0.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 14.50% vs -8.19% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 31.86% vs -34.73% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
15,250.60
13,309.70
14.58%
Operating Profit (PBDIT) excl Other Income
3,595.20
3,101.30
15.93%
Interest
214.90
264.20
-18.66%
Exceptional Items
71.30
570.40
-87.50%
Consolidate Net Profit
1,686.60
1,858.50
-9.25%
Operating Profit Margin (Excl OI)
145.50%
139.70%
0.58%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.58% vs 4.59% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -9.25% vs 6.33% in Dec 2024
About Pharmaron Beijing Co., Ltd. 
Pharmaron Beijing Co., Ltd.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






